Krystal Biotech drops as investors digest Q1 update despite $116.4M VYJUVEK revenue
Krystal Biotech shares slid about 3% after releasing Q1 2026 results showing VYJUVEK global net product revenue of $116.4 million, up 32% year over year. The pullback looks like post-results repositioning as investors digest the update despite strong sales momentum and a large cash balance.
1. What’s moving the stock
Krystal Biotech (KRYS) is down about 3% after publishing its first-quarter 2026 financial and operating results on May 4, 2026. The company reported Q1 VYJUVEK global net product revenue of $116.4 million, representing 32% growth versus the prior-year quarter, and highlighted cumulative VYJUVEK net product revenue since launch of $846.7 million. (globenewswire.com)
2. Key numbers investors are reacting to
Beyond the revenue print, investors are weighing profitability and balance-sheet details included with the quarterly filing and business update. The quarterly report also outlined cash, cash equivalents and investments and discussed drivers of operating cash flow changes versus the prior year, providing additional context for how fast the company is scaling commercialization while funding pipeline programs. (stocktitan.net)
3. Why it can be down on strong results
A down move after a headline beat is often driven by expectations and positioning rather than the top-line number alone, especially in a stock that has already priced in strong VYJUVEK momentum. With KRYS sitting near the high-$200s, today’s decline appears consistent with profit-taking and a “sell-the-news” reaction as traders reassess valuation and the cadence of upcoming catalysts following the Q1 update. (globenewswire.com)